



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, D.C. 20231 on May 28, 2001

Dara M. Kendall 43,709
Name of Attorney Registration No.
Dara M. Kendall
Signature of Attorney/Agent

#5 165.
JUN 07 2001
RECEIVED

TECH CENTER 1600/2900/670

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of :
D. N. RUBINGH ET AL. : Confirmation No.: 8554
Serial No.: 09/618,235 : Group Art Unit: 1652
Filed: July 18, 2000 : Examiner:

For: PROTEASE CONJUGATES HAVING STERICALLY PROTECTED EPITOPE REGIONS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

(With Certification)

Commissioner For Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO-1449 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO-1449 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

☒ 37 C.F.R. §1.97(c) with certification - **After 3 months from filing and after First Office Action but BEFORE Final Action, an action which otherwise closes prosecution, or Notice of Allowance**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicants have not received a final action under §1.113, an action which otherwise closes prosecution, or a notice of allowance under §1.311 as of the date of this submission.

☒ A certification as specified in 37 C.F.R. §1.97(e) is submitted herewith.

☐ 37 C.F.R. §1.97 (d) with fee and certification - **After 3 months from filing and after Final Office Action or Notice of Allowance, or an action which otherwise closes prosecution, BUT BEFORE Issue Fee paid**

This information disclosure statement, filed under 37 C.F.R. §1.97 (d), is being submitted after receipt of a final action under Section §1.113, or a notice of allowance under Section §1.311, or an action which otherwise closes prosecution, but before (or simultaneously with), the payment of the issue fee.


The Commissioner is hereby authorized to charge payment of fee (processing fee under 37 CFR 1.17(i)) for this petition under 37 C.F.R. §1.97(d) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed herewith for this purpose.


☒ Certification under 37 C.F.R. §1.97(e):

☒ (1) I hereby certify that each item of information contained in this information disclosure statement was cited for the first time in any communication in a counterpart application from a foreign patent office, not more than three months prior to the filing of this information disclosure statement

☐ (2) I hereby certify that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement.

Respectfully submitted,

By 
Dara M. Kendall
Attorney for Applicants
Registration No. 43,709
(513) 627-0081

, 2001
Miami Valley Laboratories
P. O. Box 538707
Cincinnati, OH 45253-8707